Celsis Adds Drug Development Services to Growing Services Portfolio
News Sep 13, 2007
Celsis International plc has announces the addition of Drug Development Services to its growing services portfolio. These new service offerings, which include ADME-Tox studies and preclinical and clinical CMC development services, are part of the company’s long-term strategy to offer comprehensive products and services to accelerate drug discovery and development.
Thirty percent of new drugs fail in the development pipeline due to toxicity profiles and side effects. By evaluating a pharmaceutical molecule’s ADME (absorption, distribution, metabolism, and excretion) properties and potential toxicity, ADME-Tox screening assays help to optimize the number of drug candidates for further development.
“Our goal is to save our customers both time and money by delivering the highest quality ADME-Tox services coupled with the best customer service and turnaround time in the industry,” said John Daniels, Vice President and General Manager of Celsis Analytical Services. “With our expanded services, we offer customers a continuum of technical expertise from pre-clinical testing through market launch.”
Since 1990, In Vitro Technologies Inc. (IVT) provided ADME-Tox products and services to pharmaceutical and biotechnology companies. Celsis’ new services became available after its acquisition of IVT in June 2006. Celsis has since expanded its service offerings, invested in instrumentation and upgraded its quality platform to GLP and GMP levels. These upgrades will be part of the company’s newly formed Development Services group, an extension of Celsis’ Analytical Services division.
The ADME-Tox services focus on in vitro drug metabolism, drug-drug interactions, permeability, absorption, organ toxicity, and plasma protein binding.
In addition, Celsis Development Services will offer CMC drug development services to serve clients from discovery through all clinical phases of drug development. CMC services will include preformulation and formulation development to provide comprehensive insight into the physicochemical properties of a drug molecule and its product formulations.
Exposure to Low Levels of BPA during Pregnancy Can Lead to Altered Brain DevelopmentNews
New research in mice provides an explanation for how exposure to the widely used chemical bisphenol A (BPA) during pregnancy, even at levels lower than the regulated “safe” human exposure level, can lead to altered brain development and behavior later in life.READ MORE
Moving Toward a Future Free of Drug-Induced Hearing LossNews
A new special publication orchestrated by five of the nation's leading hearing experts compiles the latest research into hearing loss caused by drugs and solvents - how it occurs, how to treat it, and how to prevent it.READ MORE
3-D Tissue Model of Developing Heart Could Aid Drug Safety Testing for Pregnant WomenNews
Parents and doctors often have to consider the mother's health as well as the potential risk regarding how medication could affect their baby. Researchers have developed a process to make a 3D tissue model that could mimic early stage human heart development, which could aid drug safety testing and help determine a drug's effects on fetal development.READ MORE
Comments | 0 ADD COMMENT
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
10th International Conference on Mass Spectrometry and Chromatography
Oct 08 - Oct 09, 2018